跳至主要内容
临床试验/NCT00998062
NCT00998062已完成不适用

Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population

AstraZeneca1 个研究点 分布在 1 个国家目标入组 30,181 人开始时间: 2009年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
30,181
试验地点
1
主要终点
Lipid fractions: high-density lipoprotein, low-density lipoprotein, and total cholesterol, and triglycerides, and dislipidemia treatments

研究概览

简要总结

The present project is aimed at determining the prevalence of LDL-C <130 mg/dl with hsCRP ≥2mg/l, and of HDL-C < 40 mg/dl in Spain together with the estimation of cardiovascular risk, to analyze the contribution of measuring hsCRP for primary prevention purposes. In a subgroup of that population a number of inflammatory and oxidative status biomarkers would be also measured to better understand the meaning of elevated hsCRP.The study aim to analyze data already collected in studies (11 studies will participate) carried out in Spain, in 10 Spanish regions, after the year 2000.

研究设计

研究类型
Observational
时间视角
Retrospective

入排标准

年龄范围
35 Years 至 74 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Have an Informed consent form signed when the patient accepted to participate in the study already performed.
  • Spanish population between
  • Data from Epidemiological studies performed after the year 2000

排除标准

  • Spanish population outside the age range
  • Data from Epidemiological studies performed before the year 2000

结局指标

主要结局

Lipid fractions: high-density lipoprotein, low-density lipoprotein, and total cholesterol, and triglycerides, and dislipidemia treatments

时间窗: retrospectively

次要结局

  • High sensitivity C reactive protein & CHR risk by Framingham adapted functions(retrospectively)
  • Lipid profile among the Spanish regions, as in the primary outcome variable(retrospectively)
  • Biomarkers: Interleukines 6 and 10, oxidized LDL, VCAM, ICAM, TNF alpha, neopterin, fibrinogen, lp(a), MMP 9 Apo A, Apo B, adiponectin, leptin, resistin, and yet other(prospectively)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验